Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MVA-BN Smallpox Vaccine

Vaccine · Immune activation, directed at orthopoxvirus VP37 (F13L) · developed by Bavarian Nordic

Phase 2 Most advanced trial
1 Registered trials

What is MVA-BN Smallpox Vaccine?

MVA-BN is a live, attenuated, non-replicating modified vaccinia Ankara vaccine used for prevention of smallpox and monkeypox. It may induce cellular and humoral immune responses against orthopoxviruses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Targets
orthopoxvirus VP37 (F13L) (antigen)
Mechanism
Immune activation, directed at orthopoxvirus VP37 (F13L)
Pathways
immune_activation, cellular_immunity, humoral_immunity
Therapy area
Infectious disease
Developer
Bavarian Nordic
In trials of
SIGA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04957485 Phase 2 Smallpox Active not recruiting SIGA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Smallpox

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.